Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.

EP: 1.An Overview of the Current Treatment Landscape for R/R FL

EP: 2.Exploring ADC/Antibody Combination Therapies in Development for R/R FL

EP: 3.An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL

EP: 4.Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL

EP: 5.Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma

Now Viewing

EP: 6.Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape

Video content above is prompted by the following:

• What are some remaining unmet needs in treating relapsed/refractory follicular lymphoma?
• What trials of interest are ongoing? What are future considerations?
• What accomplishments in this space are you most proud of?
• What are you most excited about in the coming year?

Recent Videos